Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Are you ready for the oncology patent cliff?

This article was originally published in Scrip

Executive Summary

New analysis has highlighted a looming patent cliff in the oncology sector. Datamonitor Healthcare's newly launched Oncology ExpiryView tool indicates that after a period of relative calm over the next few years, 2018-2022 will see $32bn of sales of cancer treatments in the seven major market at risk as a result of patent expiries. Roche will be particularly threatened, followed by Celgene and then Novartis.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts